Results 181 to 190 of about 1,278 (268)

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B‐cell lymphoma limits applicability to clinical practice

open access: yesBritish Journal of Haematology, EarlyView.
Summary Therapeutic options for relapsed or refractory diffuse large B‐cell lymphoma (rDLBCL) have expanded following accelerated approvals based largely on surrogate end‐points, yet confirmatory studies have not consistently reproduced these benefits across all agents, and outcomes for many patients remain poor.
Elizabeth Goodall   +11 more
wiley   +1 more source

Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non‐Hodgkin lymphomas

open access: yesBritish Journal of Haematology, EarlyView.
Optical genome mapping (OGM) is feasible on fresh and frozen tissue lymphoma samples and demonstrated its added value for accurate diagnostic classification. OGM surpasses karyotype and FISH in refining diagnoses of lymphoma, identifying class‐defining rearrangements along with prognostic markers.
Coura Fall   +15 more
wiley   +1 more source

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani   +10 more
wiley   +1 more source

Harmonizing 10,000 connectomes: site-invariant representation learning for multi-site analysis of network connectivity and cognitive impairment. [PDF]

open access: yesJ Med Imaging (Bellingham)
Newlin NR   +20 more
europepmc   +1 more source

The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection

open access: yesBJU International, EarlyView.
Background Penile cancer is a rare malignancy, with an Australian incidence of 0.6 in 100 000 men, with a wide range of clinical presentations, from localised, curable tumours to aggressive forms with high morbidity and mortality. Epidemiological data and management guidelines for penile cancer in Australia are limited.
Henry Y.C. Pan   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy